OncoMatch/Clinical Trials/NCT04215003
A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC
Is NCT04215003 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including A and B for breast cancer.
Treatment: A · B · CL4 — This is a Phase Ib/II, prospective , open-label, single center, Bayesian adaptive design, umbrella study evaluating the efficacy and safety of neo-adjuvant therapy in patients with breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage IIB, IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Naïve to chemotherapy or hormonal treatments
Cannot have received: hormonal therapy
Naïve to chemotherapy or hormonal treatments
Cannot have received: radiotherapy
Previous regional or systemic treatment for breast cancer (include but not limited to chemotherapy, radiotherapy, targeted therapy, other clinical trials)
Cannot have received: targeted therapy
Previous regional or systemic treatment for breast cancer (include but not limited to chemotherapy, radiotherapy, targeted therapy, other clinical trials)
Cannot have received: other clinical trials
Previous regional or systemic treatment for breast cancer (include but not limited to chemotherapy, radiotherapy, targeted therapy, other clinical trials)
Lab requirements
Blood counts
neutrophil count ≥ 1.5x10^9/L, hemoglobin level ≥ 100 g/L, Platelets ≥ 100 x 10^9/L
Kidney function
serum creatinine ≤110μmol/L, urea nitrogen ≤7.1mmol/L
Liver function
serum aminotransferase (AST) ≤ 60U/L, serum total bilirubin ≤ 2.5 times ULN
Cardiac function
Normal heart function, with normal ECG and LVEF ≥ 55%
Adequate bone marrow function, blood routine examination shows neutrophil count ≥ 1.5x109/L, hemoglobin level ≥ 100 g/L, Platelets ≥ 100 x 109/L Adequate liver and kidney function, serum aminotransferase (AST) ≤ 60U/L, serum total bilirubin ≤ 2.5 times ULN, serum creatinine ≤110μmol/L, urea nitrogen ≤7.1mmol/L ... Normal heart function, with normal ECG and LVEF ≥ 55%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify